|
|
 |
|
Viewing report
|
|
|
|
Next Generation Drugs: Acceleration Through Innovation
Business Insights, March 2002
The pharmaceutical industry is now immersed in a wave of technological innovation to help accelerate drug discovery and development. However, selecting the most beneficial technological systems to reduce discovery and development timelines involves due consideration of a company''s R&D focus, pipeline commitments, synergies to enhance R&D programmes, and analysis of risk and competition. Next Generation Drugs: Acceleration through innovation is a new management report examining the technological innovations that are being employed by the pharmaceutical majors to expedite discovery research and R&D. Key areas of review include genomics, proteomics, pharmacogenomics, bioinformatics, and cheminformatics in addition to other key enabling high technology discovery and development platforms. This new report also reviews how companies are accelerating discovery through strategic collaborations, enhancement of in-house expertise, and by focusing on specific diseases or small molecules to optimize their future business plans.
Customers who bought this item also bought
Biomarkers, Tests and Trends for Drug R&D
Success with Biobetters: Young Biobetters Companies and Pipelines
RNA interference (RNAi) - Global Strategic Business Report
Bioinformatics in Drug Discovery
Biomarkers: Discovery Techniques and Applications – A Global Market Overview
Biotech for Wellness: Driving Successful R&D and Licensing in Nutraceuticals through New Business Models and Collaboration
DNA Sequencing - Technologies, Markets and Companies
Stem Cells Market And Drug Discovery Applications, 2009-2015
Systems Biology in Biotech and Pharma: A New Paradigm for Innovation
Driving Drug and Diagnostic R&D: The Undeniable Influence of Biomarkers
|
|
|
|
